Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Optimized turmeric extract reduces β-Amyloid and phosphorylated Tau protein burden in Alzheimer's transgenic mice.

Shytle RD, Tan J, Bickford PC, Rezai-Zadeh K, Hou L, Zeng J, Sanberg PR, Sanberg CD, Alberte RS, Fink RC, Roschek B Jr.

Curr Alzheimer Res. 2012 May;9(4):500-6.

2.

Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles.

Chu J, Lauretti E, Craige CP, Praticò D.

J Alzheimers Dis. 2014;41(3):729-37. doi: 10.3233/JAD-140105.

PMID:
24662099
3.
4.

Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro.

Ma QL, Lim GP, Harris-White ME, Yang F, Ambegaokar SS, Ubeda OJ, Glabe CG, Teter B, Frautschy SA, Cole GM.

J Neurosci Res. 2006 Feb 15;83(3):374-84.

PMID:
16385556
6.

Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model.

Durairajan SS, Liu LF, Lu JH, Chen LL, Yuan Q, Chung SK, Huang L, Li XS, Huang JD, Li M.

Neurobiol Aging. 2012 Dec;33(12):2903-19. doi: 10.1016/j.neurobiolaging.2012.02.016.

PMID:
22459600
7.

Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.

Natunen T, Takalo M, Kemppainen S, Leskelä S, Marttinen M, Kurkinen KM, Pursiheimo JP, Sarajärvi T, Viswanathan J, Gabbouj S, Solje E, Tahvanainen E, Pirttimäki T, Kurki M, Paananen J, Rauramaa T, Miettinen P, Mäkinen P, Leinonen V, Soininen H, Airenne K, Tanzi RE, Tanila H, Haapasalo A, Hiltunen M.

Neurobiol Dis. 2016 Jan;85:187-205. doi: 10.1016/j.nbd.2015.11.005.

PMID:
26563932
8.

Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.

Zago W, Buttini M, Comery TA, Nishioka C, Gardai SJ, Seubert P, Games D, Bard F, Schenk D, Kinney GG.

J Neurosci. 2012 Feb 22;32(8):2696-702. doi: 10.1523/JNEUROSCI.1676-11.2012.

9.

Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease.

Manczak M, Mao P, Nakamura K, Bebbington C, Park B, Reddy PH.

Hum Mol Genet. 2009 Oct 15;18(20):3876-93. doi: 10.1093/hmg/ddp331.

10.
11.

Suppression of Alzheimer's disease-related phenotypes by expression of heat shock protein 70 in mice.

Hoshino T, Murao N, Namba T, Takehara M, Adachi H, Katsuno M, Sobue G, Matsushima T, Suzuki T, Mizushima T.

J Neurosci. 2011 Apr 6;31(14):5225-34. doi: 10.1523/JNEUROSCI.5478-10.2011.

12.

Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer's transgenic mice.

Dobarro M, Gerenu G, Ramírez MJ.

Int J Neuropsychopharmacol. 2013 Nov;16(10):2245-57. doi: 10.1017/S1461145713000631.

PMID:
23768694
13.

L-3-n-butylphthalide reduces tau phosphorylation and improves cognitive deficits in AβPP/PS1-Alzheimer's transgenic mice.

Peng Y, Hu Y, Xu S, Li P, Li J, Lu L, Yang H, Feng N, Wang L, Wang X.

J Alzheimers Dis. 2012;29(2):379-91. doi: 10.3233/JAD-2011-111577.

PMID:
22233765
14.

L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease.

Peng Y, Sun J, Hon S, Nylander AN, Xia W, Feng Y, Wang X, Lemere CA.

J Neurosci. 2010 Jun 16;30(24):8180-9. doi: 10.1523/JNEUROSCI.0340-10.2010.

15.

Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease.

Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C, March A, Ait-Ghezala G, Mullan MJ.

J Neuroinflammation. 2010 Mar 8;7:17. doi: 10.1186/1742-2094-7-17.

16.

Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice.

Plaschke K, Kopitz J, Siegelin M, Schliebs R, Salkovic-Petrisic M, Riederer P, Hoyer S.

J Alzheimers Dis. 2010;19(2):691-704. doi: 10.3233/JAD-2010-1270.

PMID:
20110613
17.

Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology.

Escribano L, Simón AM, Gimeno E, Cuadrado-Tejedor M, López de Maturana R, García-Osta A, Ricobaraza A, Pérez-Mediavilla A, Del Río J, Frechilla D.

Neuropsychopharmacology. 2010 Jun;35(7):1593-604. doi: 10.1038/npp.2010.32.

18.

Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease.

Kawarabayashi T, Shoji M, Younkin LH, Wen-Lang L, Dickson DW, Murakami T, Matsubara E, Abe K, Ashe KH, Younkin SG.

J Neurosci. 2004 Apr 14;24(15):3801-9.

19.

Baicalein reduces β-amyloid and promotes nonamyloidogenic amyloid precursor protein processing in an Alzheimer's disease transgenic mouse model.

Zhang SQ, Obregon D, Ehrhart J, Deng J, Tian J, Hou H, Giunta B, Sawmiller D, Tan J.

J Neurosci Res. 2013 Sep;91(9):1239-46. doi: 10.1002/jnr.23244.

20.

Amyloid-β pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset.

Dionísio PA, Amaral JD, Ribeiro MF, Lo AC, D'Hooge R, Rodrigues CM.

Neurobiol Aging. 2015 Jan;36(1):228-40. doi: 10.1016/j.neurobiolaging.2014.08.034.

PMID:
25443293

Supplemental Content

Support Center